The Importance of Chemotherapy in Treating Triple Negative Breast Cancer

About 10 to 20% of breast cancers are triple negative, one of the most aggressive forms of breast cancer. Triple negative breast cancer (TNBC) patients have a 77% five-year survival rate compared to 93% of women with other types of breast cancer, in part because they are less likely to pursue chemotherapy treatments that offer the highest chance of survival.

In an effort to improve survival rates and health outcomes, the CDC Division of Cancer Prevention and Control engaged with the National Association of Chronic Disease Directors and health simulation company Kognito, the leading developer of health education simulations, to create “Talk to Someone: Triple Negative Breast Cancer.”

“Talk to Someone: Triple Negative Breast Cancer” is an online and mobile app in which TNBC patients engage in an interactive conversation with Linda, a virtual TNBC survivor. Users lead the conversation by posing their questions about TNBC, chemotherapy, life during treatment, and survivorship to Linda. The objectives of the conversation are for patients to better understand their diagnosis, better understand advantages of chemotherapy, and to know what to expect from treatment, in order to raise motivation to pursue chemotherapy.

“Talk to Someone: Triple Negative Breast Cancer” is available online and as a mobile app for the general public and for oncology providers to e-prescribe to newly diagnosed patients.

To talk with Linda about diagnosis and treatment, Click Here, or download the app on the App Store or Google Play Store.